Phase 3 Lung Cancer Trial, Recruiting NCT07170995 Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT07170995
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are joining the trial willingly and are able to sign a consent form
  • You are between 18 and 75 years old (any gender)
  • You have been recently diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body, have not received any treatment for it yet, and cannot be treated with surgery or radiation aimed at curing the disease
  • A lab test has confirmed a specific marker on your tumor called PD-L1 before you enter the trial
  • You are generally active and able to care for yourself, with little or no limitation in daily activity (confirm with trial site)
  • You are expected to live for at least 3 months or more
  • You have at least one area of cancer that can be measured on a scan, according to standard guidelines

Who may not be able to join:

  • You have cancer that has spread to the brain and has not been treated, or cancer has spread to the lining around the brain or is pressing on the spinal cord
  • You have fluid build-up around the lungs, heart, or in the abdomen that is causing symptoms and is not under control
  • You have had or currently have another type of cancer
  • You have an active or previously diagnosed condition where your immune system attacks your own body (confirm with trial site)
  • You currently have or have had hepatitis B or hepatitis C, or have a history of a weakened immune system
  • You have had or currently have scarring or inflammation of the lungs (including from medication or radiation)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 021-61053363

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Registry
ClinicalTrials.gov
Start date
22 October 2025
Est. completion
1 December 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS) by Blinded Independent Central Review [BICR]; OS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov